Por motivos de mantenimiento se ha deshabilitado el inicio de sesión temporalmente. Rogamos disculpen las molestias.
Mostrar el registro sencillo del ítem
Artículo
Multivalent Calixarene-Based Liposomes as Platforms for Gene and Drug Delivery
dc.creator | Lebrón Romero, José Antonio | es |
dc.creator | López López, Manuel | es |
dc.creator | García Calderón, Clara Beatriz | es |
dc.creator | Valle Rosado, Iván | es |
dc.creator | Romero Balestra, Fernando | es |
dc.creator | Huertas Sánchez, Pablo | es |
dc.creator | Rodik, Roman V | es |
dc.creator | Kalchenko, Vitaly I. | es |
dc.creator | Bernal Pérez, Eva | es |
dc.creator | Moyá Morán, María Luisa | es |
dc.creator | López-Cornejo, María del Pilar | es |
dc.creator | Ostos Marcos, Francisco José | es |
dc.date.accessioned | 2021-08-30T09:43:01Z | |
dc.date.available | 2021-08-30T09:43:01Z | |
dc.date.issued | 2021-08 | |
dc.identifier.citation | Lebrón Romero, J.A., López López, M., García Calderón, C.B., Valle Rosado, I., Romero Balestra, F., Huertas Sánchez, P.,...,Ostos Marcos, F.J. (2021). Multivalent Calixarene-Based Liposomes as Platforms for Gene and Drug Delivery. Pharmaceutics, 13 (8), 1250. | |
dc.identifier.issn | 1999-4923 | es |
dc.identifier.uri | https://hdl.handle.net/11441/125213 | |
dc.description.abstract | The formation of calixarene-based liposomes was investigated, and the characterization of these nanostructures was carried out using several techniques. Four amphiphilic calixarenes were used. The length of the hydrophobic chains attached to the lower rim as well as the nature of the polar group present in the upper rim of the calixarenes were varied. The lipid bilayer was formed with one calixarene and with the phospholipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, DOPE. The cytotoxicity of the liposomes for various cell lines was also studied. From the results obtained, the liposomes formed with the least cytotoxic calixarene, (TEAC12)4, were used as nanocarriers of both nucleic acids and the antineoplastic drug doxorubicin, DOX. Results showed that (TEAC12)4/DOPE/p-EGFP-C1 lipoplexes, of a given composition, can transfect the genetic material, although the transfection efficiency substantially increases in the presence of an additional amount of DOPE as coadjuvant. On the other hand, the (TEAC12)4/DOPE liposomes present a high doxorubicin encapsulation efficiency, and a slow controlled release, which could diminish the side effects of the drug. | es |
dc.description.sponsorship | España. Consejería de Conocimiento, Innovación y Universidades de la Junta de Andalucía (FQM-206, FQM-274, and PY20-01234) | es |
dc.description.sponsorship | VI Plan Propio Universidad de Sevilla (PP2019/00000748), RTI2018-100692-B-100; P18-RT-1271; PI18-0005-2018; VI-PP AY.SUPLEM2019; RYC-2015-18670 | es |
dc.description.sponsorship | España Ministry of Science and Innovation-Agencia Estatal de Investigación/10.13039/501100011033 (P.H.) R+D+I grant PID2019-104195G | es |
dc.format | application/pdf | es |
dc.format.extent | 26 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Pharmaceutics, 13 (8), 1250. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | cationic calix[4]arenes | es |
dc.subject | liposomes | es |
dc.subject | nucleic acids | es |
dc.subject | transfection efficiency | es |
dc.subject | doxorubicin | es |
dc.subject | encapsulation | es |
dc.title | Multivalent Calixarene-Based Liposomes as Platforms for Gene and Drug Delivery | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Química Física | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Genética | es |
dc.relation.projectID | (FQM-206, FQM-274, and PY20-01234) | es |
dc.relation.projectID | (PP2019/00000748), RTI2018-100692-B-100; P18-RT-1271; PI18-0005-2018; VI-PP AY.SUPLEM2019; RYC-2015-18670 | es |
dc.relation.projectID | 10.13039/501100011033 (P.H.) R+D+I grant PID2019-104195G | es |
dc.relation.publisherversion | http://dx.doi.org/10.3390/pharmaceutics13081250 | es |
dc.identifier.doi | 10.3390/pharmaceutics13081250 | es |
dc.journaltitle | Pharmaceutics | es |
dc.publication.volumen | 13 | es |
dc.publication.issue | 8 | es |
dc.publication.endPage | 1250 | es |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
pubpharmaceutics-13-01250-v2.pdf | 7.740Mb | [PDF] | Ver/ | |